Callan Capital LLC Has $808,000 Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Callan Capital LLC increased its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 103.9% in the 2nd quarter, Holdings Channel.com reports. The firm owned 10,358 shares of the company’s stock after acquiring an additional 5,277 shares during the quarter. Callan Capital LLC’s holdings in AstraZeneca were worth $808,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the business. Ieq Capital LLC lifted its position in shares of AstraZeneca by 32.1% during the 2nd quarter. Ieq Capital LLC now owns 37,265 shares of the company’s stock worth $2,906,000 after purchasing an additional 9,059 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of AstraZeneca during the 2nd quarter worth about $1,075,000. Hsbc Holdings PLC lifted its position in shares of AstraZeneca by 750.3% during the 2nd quarter. Hsbc Holdings PLC now owns 1,283,274 shares of the company’s stock worth $100,523,000 after purchasing an additional 1,132,362 shares during the last quarter. Vanguard Personalized Indexing Management LLC lifted its position in shares of AstraZeneca by 51.8% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 93,467 shares of the company’s stock worth $7,289,000 after purchasing an additional 31,893 shares during the last quarter. Finally, Argent Trust Co lifted its position in shares of AstraZeneca by 9.5% during the 2nd quarter. Argent Trust Co now owns 7,136 shares of the company’s stock worth $557,000 after purchasing an additional 618 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on AZN. The Goldman Sachs Group began coverage on AstraZeneca in a research report on Thursday, May 30th. They set a “buy” rating and a $97.00 price objective for the company. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Barclays raised AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Citigroup raised AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Finally, TD Cowen upped their price target on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, AstraZeneca currently has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Trading Up 0.4 %

Shares of AZN opened at $78.90 on Friday. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The stock has a 50 day simple moving average of $81.80 and a 200-day simple moving average of $76.46. The stock has a market cap of $244.63 billion, a PE ratio of 38.68, a PEG ratio of 1.49 and a beta of 0.47.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.99 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.01. The business had revenue of $12.45 billion for the quarter, compared to analyst estimates of $12.62 billion. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. AstraZeneca’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the prior year, the company earned $1.08 EPS. On average, sell-side analysts predict that AstraZeneca PLC will post 4.05 EPS for the current fiscal year.

AstraZeneca Cuts Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Monday, September 9th. Investors of record on Friday, August 9th were given a dividend of $0.49 per share. The ex-dividend date of this dividend was Friday, August 9th. This represents a yield of 1.8%. AstraZeneca’s dividend payout ratio (DPR) is presently 48.04%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.